Pulmonary Vascular Disease |

Prevalence of COPD in Patients With Pulmonary Arterial Hypertension and Its Effect on Severity, Mortality, and Functional Status FREE TO VIEW

Massa Zantah, MD; Julianne Nichols, DO; Vanessa Yap, MD; Raymond Foley, DO; Debapriya Datta, MD
Author and Funding Information

University of CT Health Center, Farmington, CT

Chest. 2015;148(4_MeetingAbstracts):948A. doi:10.1378/chest.2260550
Text Size: A A A
Published online


SESSION TITLE: Pulmonary Arterial Hypertension Posters I

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 28, 2015 at 01:30 PM - 02:30 PM

PURPOSE: Studies have shown that pulmonary hypertension (PH) occurs in about 30% of patients with COPD. The prevalence of COPD in Pulmonary Arterial Hypertension (PAH) and its impact on the disease has not been extensively studied.The objective of this study was to determine prevalence of COPD in patients with PAH and its effect on disease severity, functional capacity and mortality.

METHODS: The medical records of patients with PAH, defined as mean pulmonary artery pressure (mPAP) ≥25mm Hg and mean pulmonary arterial wedge pressure (PAWP) ≤ 15mmHg, being treated at the PH Center at our institution, over the last 6 years (2007 to 2013) was reviewed. The following data was obtained -age, gender, mPAP, pulmonary vascular resistance (PVR), presence of COPD, 6MWD, NYHA class; and alive or expired during follow-up. Impact of COPD on outcomes (severity of PAH measured by mPAP, and PVR; functional status as measured by 6MWD and NYHA class and survival) was determined by univariate analysis, using independent t-test.p< 0.0.5 was deemed statistically significant.

RESULTS: Of 75 patients, 75% were female; mean age was 64 + 14 years; mean mPAP was 42 + 13 mmHg; mean PVR of 573 + 384 dynes/sec/cm5. 38% percent patients expired during follow-up. COPD was present in 5% patients. All studied parameters in PAH patients with COPD/ COPD are as follows: Parameters: ---------------→ PAH with COPD vs. PAH without COPD mPAP--------------------------------------→ 44 ±13 vs. 41±13 (mmHg) [p=0.9] PVR -------------------------------------→ 371±158 vs.582±397 (dynes/sec/cm) [p=0.6] 6MWD ---------------------------------→ 358±134 vs. 351± 121(m) [p=0.9] NYHA class ---------------------------------→ 2 versus 2 [p=0.8] Expired ------------------------------------→ 2/4 versus 21/71. [p=0.4]. There was no statistically significant difference in studied parameters in the 2 groups.

CONCLUSIONS: Concomitant COPD in PAH is uncommon. It is not associated with more severe disease and doesnot appear to affect survival or functional capacity, as would be expected.

CLINICAL IMPLICATIONS: More studies, on a larger number number of subjects, are needed to confirm these findings.

DISCLOSURE: The following authors have nothing to disclose: Massa Zantah, Julianne Nichols, Vanessa Yap, Raymond Foley, Debapriya Datta

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543